Medical Gas Research

RESEARCH ARTICLE
Year
: 2023  |  Volume : 13  |  Issue : 3  |  Page : 112--117

Efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial


Hesameddin Modir1, Behnam Mahmoodiyeh1, Mehran Shayganfard2, Ayda Abdus3, Amir Almasi-Hashiani4 
1 Anesthesiology Department Arak University of Medical Sciences, Arak, Iran
2 Departments of Psychiatry Arak University of Medical Sciences, Arak, Iran
3 Student Research Committee Arak University of Medical Sciences, Arak, Iran
4 Department of Epidemiology, School of Health, Arak University of Medical Sciences, Arak, Iran

Correspondence Address:
Behnam Mahmoodiyeh
Anesthesiology Department Arak University of Medical Sciences, Arak, Iran
Iran

Electroconvulsive therapy (ECT) is one of the therapeutic opportunities for patients with psychological disorders when they may decline to take medication. We sought to systematically compare the anesthetic efficacy of ketamine, propofol, and dexmedetomidine for electroconvulsive therapy in treatment-resistant major depressive disorder patients. This double-blind trial enrolled treatment-resistant major depressive disorder patients (n = 85) who had been hospitalized for ECT in the Amir Kabir Hospital’s psychiatric ward (Arak, Iran). The ketamine, propofol, and dexmedetomidine groups received a dose of 0.2 μg/kg ketamine, 1.5 mg/kg propofol, and 0.8 mg/kg dexmedetomidine, respectively. In all intervention groups, 10 mL of interventional drugs was injected intravenously for 10 minutes, and in the placebo group, 10 mL of normal saline was given over the same period. The dexmedetomidine group’s blood pressure was revealed comparatively lower at all times. Dexmedetomidine-treated patients showed their marked satisfaction, while those treated with propofol had shorter recovery time, shorter seizure duration, and shorter time to achieve an Aldrete score of 9–10 and increased relaxation, and next dexmedetomidine produced deeper relaxation. Propofol could shorten recovery time and seizure duration, and enhance relaxation, while dexmedetomidine was associated with higher patient satisfaction. Considering that any anesthetic which does not shorten seizure duration may serve efficiently for ECT and that ketamine-treated patients had more prolonged seizure duration, the preferred drug can hence be considered from various angles, thereby offering anesthetic agents with highly favorable efficacy in treatment-resistant major depressive disorder patients needing ECT. The drug choice thus depends on physical conditions, underlying diseases, and psychiatrist consultation.


How to cite this article:
Modir H, Mahmoodiyeh B, Shayganfard M, Abdus A, Almasi-Hashiani A. Efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial.Med Gas Res 2023;13:112-117


How to cite this URL:
Modir H, Mahmoodiyeh B, Shayganfard M, Abdus A, Almasi-Hashiani A. Efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial. Med Gas Res [serial online] 2023 [cited 2023 Feb 9 ];13:112-117
Available from: https://www.medgasres.com/article.asp?issn=2045-9912;year=2023;volume=13;issue=3;spage=112;epage=117;aulast=Modir;type=0